JPMorgan Raises Price Target on Globe Life Inc. (GL) to $181 and Reiterates an Overweight Rating

Globe Life Inc. (NYSE:GL) is included among the 10 Most Profitable Undervalued Stocks to Buy

On February 6, 2026, JPMorgan analyst Jimmy Bhullar raised his price target on Globe Life Inc. (NYSE:GL) to $181 from $180 and reiterated an Overweight rating. The modest adjustment followed the company’s latest earnings update and the company’s fiscal 2026 earnings outlook.

A day earlier, on February 5, 2026, Globe Life Inc. (NYSE:GL) reported fourth-quarter revenue of $1.52 billion, slightly below the consensus estimate of $1.53 billion. While the top line came in slightly lower than consensus expectations, investor focus centered more on the company’s forward outlook. For fiscal year 2026, Globe Life Inc. (NYSE:GL) reportedly sees earnings of $14.95 to $15.65 per share, compared with a consensus estimate of $15.03. The range suggests management sees room for continued earnings growth.

Globe Life Inc. (NYSE:GL) provides life and supplemental health insurance products primarily to lower-middle- and middle-income households in the United States. Through its subsidiaries, the company operates across Life Insurance, Supplemental Health Insurance, and Investments, offering a mix of whole and term life policies alongside Medicare supplement and limited-benefit health products such as accident, cancer, and critical illness coverage.

While we acknowledge the potential of GL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and  12 Best Nuclear Energy Stocks to Buy Now

Disclosure: None.